Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics

 ZUG, Switzerland 

Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane® syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3

Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7

The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8

These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field

 

(BUSINESS WIRE)--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/

The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients.

 

“Developing this new syringe in close collaboration with practitioners to address their specific needs has really set it apart. Repetitive hand movements like performing numerous injections every day can lead to strain and reduced mobility, but the syringe’s ergonomic design, with a cushioned finger grip and thumb rest ensure maximum comfort when injecting, supporting consistent, high‑quality results for patients.”

 

DR. LUDDI LUIZ OLIVEIRA

PLASTIC SURGEON

BRAZIL

 

Designed in collaboration with over 70 aesthetics practitioners, the next-generation Restylane syringe was optimized for ergonomic functionality, ease of aspiration, ease of operation, and a premium look and feel, resulting in an innovative syringe that supports practitioners with delivering premium results. 4,5,7,9 Additionally, the syringe was designed with sustainability in mind, with compact paper-only carton packaging that is 100% recyclable and reduces in-clinic waste by up to 30% based on volume reduction. 8,11

Galderma’s versatile Restylane portfolio is the only hyaluronic acid (HA) range offering four distinct technologies, NASHA®, NASHA HD™, OBT™, and SB-NASHA™, that offer firmer gels that provide contouring and structural support, to soft, flexible formulations that smooth facial lines and wrinkles for a more youthful look.12-19 With HA closest to the skin’s own, it is designed to deliver personalized, natural-looking outcomes that provide contour, definition, and hydration, meeting diverse patient needs across key areas of the face, décolletage, and in the hands.12-15,20-22 The new state-of-the-art syringe represents the next step in Restylane’s evolution, with a novel way to deliver its trusted premium results.

 

“This next-generation syringe reflects the latest advancements in injection design, giving aesthetic practitioners greater precision, improved ergonomics, and enhanced control. By refining every element of the injector experience, we aim to help clinicians deliver consistently premium results for their patients. Through direct collaboration with practitioners, Galderma continues to push the boundaries of aesthetic innovation, and we remain steadfast in our commitment to driving the field forwards."

 

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.

GLOBAL HEAD OF R&D

GALDERMA

 

The next-generation syringe is now approved for use in the EU, the U.S., and Canada with the NASHA® lidocaine range of Restylane products including, Restylane Lyft™ Lidocaine, Restylane Eyelight™ and Restylane-L™ (known as Classyc™ Lidocaine in some markets).1-3

With over 30 years of innovation and more than 77 million treatments administered worldwide, Restylane’s has an iconic heritage as a trusted, science-backed HA treatment that consistently delivers premium results. 23,24 Building on this heritage, the new state-of-the-art Restylane syringe demonstrates Galderma’s continued innovation, and solidifies its position at the forefront of aesthetics.

About the Restylane portfolio

Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results. 21,25-27 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.28-31 Powered by NASHA®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.12-19 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.12,21,22

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1.

 

Galderma. Data on file. U.S. FDA Restylane syringe PMA supplement approval letter

2.

 

Galderma. Data on file. Health Canada Restylane Medical Device License

3.

 

Galderma. Data on file. Dekra Restylane next generation syringe report

4.

 

Galderma. Data on file. MA-64737

5.

 

Galderma. Data on file. MA-56005

6.

 

Galderma. Data on file. Restylane next generation syringe HCP survey

7.

 

Galderma. Data on file. Design and development of the next generation syringe

8.

 

Galderma. Data on file. Vimer S.r.l. Declaration of recycling compliance. 2025

9.

 

Galderma. Data on file. MA-59168

10.

 

Galderma. Data on file. MA-65164

11.

 

Galderma. Data on file. MA-63907

12.

 

Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.

13.

 

Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.

14.

 

Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.

15.

 

Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.

16.

 

Nikolis A, et al. A new NASHA-HD, high G’ hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

17.

 

Rivers J, et al. Effectiveness and safety of Restylane® Lyft™ Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

18.

 

Moradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the décolletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

19.

 

Nestor, M. Safety and effectiveness of an OBT™ hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

20.

 

Galderma Data on file. MA-56724. X-strain and G’ including Shaype.

21.

 

Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.

22.

 

Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after hyaluronic acid filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.13205.

23.

 

Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.

24.

 

Fabi SG, et al. The potential role of biostimulators/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.

25.

 

Restylane. U.S. Instructions for use. Available online. Accessed January 2026.

26.

 

Nikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? Aesthet Surg J Open Forum. 2020;2(1):1–12. doi: 10.1093/asjof/ojaa005.

27.

 

Talarico S, et al. High patient satisfaction of a hyaluronic acid filler producing enduring full-facial volume restoration: an 18- month open multicenter study. Dermatol Surg. 2015;41 (12):1361–1369. doi: 10.1097/DSS.0000000000000549.

28.

 

Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.

29.

 

Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.

30.

 

Galderma. Data on file. MA-58650. Degree of modification of HA fillers.

31.

 

Seo KK. Facial volumization with fillers. Springer. 2021;29–83. doi: 10.1007/978-981-33-6212-3_2.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224651688/en/

Permalink

https://www.aetoswire.com/en/news/2502202653526

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 2025

 Strong margin improvement to 16.3% in FY 2025

Positive growth outlook with continued margin expansion in 2026

New EUR 200 million share buyback

 

(BUSINESS WIRE)--Bureau Veritas (BOURSE:BVI):

2025 key figures1

› Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis,

› Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency,

› Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024,

› Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024,

› Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency,

› Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024,

› Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2,

› Adjusted net debt/EBITDA ratio of 1.1x as of December 31, 2025, slightly up versus last year,

› Proposed dividend of EUR 0.92 per share3, up 2.2% year-on-year, payable in full in cash.

2025 highlights

› 2025 financial targets of revenue, margin and cash met or exceeded,

› Strong drivers of portfolio organic growth from higher energy investments, from the ongoing buildup of digital infrastructure and from clients demand for corporate and enterprise risk assessment solutions,

› Progressive LEAP I 28 strategy execution in its second year yielding tangible impact on operational leverage and functional scalability,

› New organization implementation to accelerate strategy execution,

› Portfolio refocusing continues with nine bolt-on acquisitions, and two divestments in non-core areas closed. These acquisitions added EUR 96 million in annualized revenue and support LEAP I 28 portfolio priorities of: i) Strengthening leadership positions in Buildings & Infrastructure; ii) Creating new strongholds in Power & Utilities and Renewables, Cybersecurity, and in Sustainability and iii) Optimizing value and impact in mature businesses; in Consumer Product Services and in Metals & Minerals. Year-to-date, three more bolt-on deals have been closed, contributing to c. EUR 5 million in annualized revenue,

› Double-digit shareholder returns based on EPS growth of c. 9% at constant currency, a dividend yield of c. 3% and enhanced by a EUR 200 million share buyback program (representing c. 1.5% of outstanding share capital).

2026 outlook

Bureau Veritas is starting the third year of LEAP I 28 strategy with sound market fundamentals. Building on a strong 2025 performance, the Group aims to deliver full year results for 2026 aligned with the financial ambition outlined in its strategy:

› Mid-to-high single-digit organic revenue growth,

› Improvement in adjusted operating margin at constant exchange rates,

› Strong cash flow generation.

Hinda Gharbi, Chief Executive Officer, commented:

“2025 was a year of solid progress for Bureau Veritas, with sector leading organic growth, strong margin expansion, and a disciplined execution of our LEAP | 28 strategy. I want to thank all our colleagues worldwide for their strong commitment and personal contributions.

In this passing year, the second of our strategic plan, we delivered results fully in line with our ambition to accelerate growth and enhance returns, supported by a strengthened portfolio and a tangible impact from our performance programs.

We again achieved double‑digit shareholder returns at constant currency, reflecting both the quality of our portfolio and the effectiveness of our strategy. With our new organizational structure now almost complete, we are better equipped to scale our product lines’ services within our regional platforms, drive cross‑selling, and elevate our customer service and stickiness.

As we start 2026, we remain focused on executing our growth and margin improvement plans, confident in the resilience of our evolving portfolio and in our ability to generate superior, sustainable value over the mid and long term. We are continuing to improve shareholder returns and will be launching a new EUR 200 million share buyback program, without hindering our M&A plans."

2025 KEY FIGURES

On February 24, 2026, the Board of Directors of Bureau Veritas approved the financial statements for the full year 2025. The main consolidated financial items are:

IN EUR MILLION	2025		2024		CHANGE		CONSTANT CURRENCY
Revenue	6,466.4		6,240.9		+3.6%		+7.3%
Adjusted operating profit(a)	1,052.9		996.2		+5.7%		+10.8%
Adjusted operating margin(a)	16.3%		16.0%		+32bps		+51bps
Operating profit	992.4		933.4		+6.3%		+11.2%
Adjusted net profit(a)	631.4		620.7		+1.7%		+8.1%
Attributable net profit	588.0		569.4		+3.3%		+9.3%
Adjusted EPS(a)	1.42		1.38		+2.8%		+9.2%
EPS	1.32		1.27		+4.3%		+10.4%
Operating cash-flow	1,006.7		1,004.8		+0.2%		+4.6%
Free cash flow(a)	824.2		843.3		(2.3)%		+2.6%
Adjusted net financial debt(a)	1,253.3		1,226.3		+2.2%
(a) Alternative performance indicators are presented, defined, and reconciled with IFRS in appendices 6 and 8 of this press release

2025 HIGHLIGHTS

2025 financial targets achieved with some exceeding expectations

› Mid-to-high single digit organic revenue growth in the full year

Group revenue in 2025 increased by 6.5% organically compared to 2024, including 6.3% in the fourth quarter, benefiting from underlying robust market trends across businesses and geographies.

› Improvement in adjusted operating margin at constant exchange rates

The Group delivered an adjusted operating margin of 16.3%, up 51 basis points at constant currency and up 32 basis points on a reported basis compared to 2024.

› Strong cash flow, with cash conversion4 above 90%

The Group achieved a strong cash flow with cash conversion of 107% in 2025.

Double-digit shareholder returns

AI: The New Insider Threat Facing Organizations

 MEUDON, France - 

 Thales 2026 Data Threat Report Finds 70% of Organizations Rank AI as Top Data Security Risk

As AI systems gain broader access to enterprise data across environments, organizations must treat data visibility and encryption as core security elements.

 

AI-enabled deepfakes and misinformation are increasing the effectiveness of identity-based attacks. Today, credential theft is the leading attack technique against cloud infrastructure (67%). Nearly 60% of companies report deepfake-driven incidents, and 48% experience damage from AI-generated misinformation

 

Investment in AI security is growing, with 30% of companies allocating dedicated budgets; however, 53% are still relying on existing security budget

 

(BUSINESS WIRE)--According to the Thales 2026 Data Threat Report, organizations across various markets including automotive, energy, finance and retail say the rapid pace of AI-driven transformation is now their biggest security challenge. Based on the report’s research, conducted by S&P Global 451 Research, 61% cite AI as their top data security risk. The concern is not only about malicious AI, but about the access it is being granted as it shifts from a tool to a trusted insider.

As enterprises embed AI into workflows, analytics, customer service, and development pipelines, these systems are being granted broad, automated access to enterprise data, often with fewer controls than those applied to human users in a corporate environment.

“Insider risk is no longer just about people. It is also about automated systems that have been trusted too quickly,” says Sebastien Cano, Senior Vice President, Cybersecurity Products at Thales. “When identity governance, access policies, or encryption are weak, AI can amplify those weaknesses across corporate environments far faster than any human ever could.”

Visibility Gaps Are Widening as AI Expands Data Reach

The report reveals a troubling disconnect between AI adoption and data control. Only 34% of organizations know where all their data resides, whatever the level of criticality, and just 39% can fully classify it. Meanwhile, nearly half (47%) of sensitive cloud data remains unencrypted.

As AI systems ingest and act on data across cloud and SaaS environments, limited visibility makes enforcing least-privilege access increasingly difficult, that is granting only the strictly necessary access rights. This increases the extent of exposure if credentials are compromised.

Identity infrastructure is now the primary attack surface. Credential theft remains the leading attack technique against cloud management infrastructure, cited by 67% of organizations experiencing cloud attacks. At the same time, 50% rank secrets management among their top application security challenges, reflecting the growing complexity of governing machine identities, API (interfaces de programmation applicative) keys, and tokens at scale.

AI Is Powering More Convincing Attacks

While organizations race to adopt AI, attackers are doing the same. Nearly 60% of companies report experiencing deepfake-driven attacks, and 48% report reputational damage tied to AI-generated misinformation or impersonation campaigns.

As AI introduces new risks, it also increases existing ones. Human error already contributes to 28% of breaches, and with automation layered on top, small mistakes can scale faster and spread wider.

Security Investment Is Shifting, But Not at the Pace of the new Risks

While organizations recognize the need to adapt, investment is not keeping pace with the rapid expansion of AI-driven access and automation. 30% now dedicate specific budgets to AI security, reflecting growing awareness. However, the majority (53%) still depend on traditional security programs built primarily for human users and perimeter-based controls. As machines increasingly authenticate, access, and act autonomously, many security strategies have yet to adjust to this shift in operating models.

“As AI becomes deeply embedded into enterprise operations, continuous data visibility and protection are no longer optional,” said Eric Hanselman, Chief Analyst at S&P Global 451 Research. “Organizations must treat data security strategy as foundational to innovation, not separate from it.”i

Trust Must Evolve as Machines Gain Access

AI is not replacing traditional threats; rather, it is intensifying them by increasing their speed, scale, and reach. As automated systems gain broader access to enterprise data, organizations must rethink identity, encryption, and data visibility as core infrastructure. The organizations that embed strong governance into their AI strategies will be better positioned to innovate securely and avoid turning AI into their newest insider threat.

For more information, please download the full report and join our webinar hosted by Eric Hanselman, Chief Analyst at S&P Global 451 Research.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services addresses several major challenges: sovereignty, security, sustainability and inclusion.

The Group invests more than €4 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, cybersecurity, quantum and cloud technologies.

Thales has more than 83,000 employees in 68 countries. In 2024, the Group generated sales of €20.6 billion.

 

 

i Thales 2026 Data Threat Report, 2026, commissioned by Thales and conducted by S&P Global 451 Research

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260225599723/en/

Permalink

https://aetoswire.com/en/news/2502202653530

Contacts

Press contact

Thales, Media Relations

Security & Cybersecurity

Marion Bonnet

+33 (0)6 60 38 48 92

marion.bonnet@thalesgroup.com

إزالة الكربون من القطاع الصناعي: Calderion وWenCo وTerravent تضخ استثمارات في Graforce لتوسيع نطاق تقنية التحلل الحراري بالبلازما عالميًا

برلين - الخميس, 26. فبراير 2026

(BUSINESS WIRE)-- أعلن تحالف المستثمرين الذي يضم صندوق Calderion (Audacia) للوقود الصناعي والتكنولوجي من الجيل التالي ومقره باريس، إلى جانب شركة تطوير البنية التحتية Terravent ومكتب WenCo العائلي، عن إغلاق جولة تمويل إستراتيجية بقيمة ملايين من اليورو (مزدوجة الرقم) لصالح شركة Graforce GmbH ومقرها برلين.

يُخصَّص هذا الاستثمار لأغراض التوسع الصناعي لتكنولوجيا التحلّل الحراري بالبلازما المملوكة لشركة Graforce، وذلك لتلبية الطلب العالمي المتزايد على الهيدروجين المنخفض الكربون المنخفض التكلفة، والغاز الاصطناعي، وحلول إزالة الكربون المتوافقة مع البُنى التحتية الصناعية القائمة.

 بديل جذري ومبتكر للعمليات التقليدية

تهدف تكنولوجيا شركة Graforce إلى استبدال الطرق التقليدية كثيفة انبعاثات ثاني أكسيد الكربون، مثل إعادة التشكيل بالبخار والتحويل الكلاسيكي للغاز، وعن طريق تطبيق البلازما على الميثان، والغاز الحيوي، وغاز الاحتراق، وغاز المدافن، تسهم هذه العملية في تحويل هذه التدفقات إلى مكوناتها الجزيئية القيمة بدلاً من إطلاقها في الغلاف الجوي.

والنتيجة هي إنتاج عالي الكفاءة للهيدروجين النظيف والغاز الاصطناعي، في حين يتم الحصول على الكربون كمواد خام صناعية عالية النقاء تبقى ضمن دورات المواد. وعند استخدام المواد الأولية الحيوية، تتيح هذه العملية تحقيق بصمة سلبية لثاني أكسيد الكربون (إزالة الكربون)؛ حيث يتم تخزين الكربون بشكل دائم بدلاً من إطلاقه في الغلاف الجوي. كما يتيح هذا المنهج المعياري الإنتاج اللامركزي مباشرة عند نقطة الاستهلاك، ما يقلل بشكل كبير من تكاليف النقل وفقدان الطاقة.

 تعاون إستراتيجي مع شركة RAG Austria AG

بالتوازي مع جولة التمويل، تعمد شركة Graforce إلى تعميق شراكتها مع شركة تخزين الطاقة RAG Austria AG، التي تقدّم دعمًا ماليًا وصناعيًا مستهدفًا لتطوير مصنع التحلل الحراري للميثان بالبلازما بشكل أكبر. وينصب تركيز هذا التعاون على تحسين النظام ودمجه في العمليات الصناعية. كما يعزز هذا التعاون مكانة شركة Graforce في مسارها نحو التشغيل الصناعي المستمر، ويزيد من كفاءة المصنع، ويدعم استخدام المصانع المعيارية في المواقع التي تتوفر فيها الطاقة المتجددة بشكل متغير.

 استخدام الأموال: التوسع الصناعي ونشر التكنولوجيا في السوق

ستُستخدم هذه الأموال في التطوير التكنولوجي، ونشر محطات صناعية إضافية، وتوسيع نطاق الأعمال في الأسواق الدولية، إذ تخطط شركة Graforce لتوسيع قدراتها الإنتاجية لتلبية الطلب المتزايد من قطاعات الصلب والكيماويات والنقل.

 بيانات الشركاء

صرح Vincent Brillault، الشريك المؤسس لصندوق Calderion، موضحًا: "بفضل انضمام شركة Graforce إلى محفظتنا، يعزز صندوق Calderion تغطيته لسلاسل قيمة الوقود من الجيل القادم، عن طريق الجمع بين تقنية احتجاز ثاني أكسيد الكربون، وتحويل الميثان باستخدام البلازما، وإنتاج الوقود الاصطناعي، إذ يسمح هذا بإنشاء مسارات متكاملة لتحويل الميثان وثاني أكسيد الكربون إلى هيدروجين وغاز اصطناعي منخفضي الكربون، بما يسهم في تحقيق أهداف إزالة الكربون من القطاع الصناعي وإنتاج الوقود المستدام لقطاعي الملاحة البحرية والطيران. إضافة إلى ذلك، توفر تكنولوجيا شركة Graforce لمستكشفي الهيدروجين الطبيعي حلاً فعالاً للاستفادة من الميثان المصاحب من دون انبعاثات ثاني أكسيد الكربون".

أضاف Jens Rötteken، المدير التنفيذي لشركة Terravent، قائلاً: "تسهم القدرة على توفير أنواع مختلفة من الغازات الإنتاجية بطريقة لامركزية وخالية من الانبعاثات في سد فجوة حيوية في سلسلة القيمة الصناعية. كما نسهم بخبرتنا الثرية في تخطيط المشروعات لإيصال هذه التكنولوجيا إلى السوق العالمية".

صرح الدكتور Jens Hanke، المدير التنفيذي لشركة Graforce GmbH، قائلاً: "يؤكد هذا الاستثمار الإمكانات الهائلة لتكنولوجيا التحلل بالبلازما لدينا من أجل تحقيق تحول مستدام في قطاع الطاقة. ونحن نتطلع للعمل معًا لجعل تكنولوجيا التحلل بالبلازما لدينا قابلة للتوسع وفعّالة من حيث التكلفة".

 نبذة عن الشركاء

 شركة Graforce GmbH، الشركة الرائدة في تقنيات إنتاج الهيدروجين والغاز الاصطناعي الخالية من ثاني أكسيد الكربون باستخدام تكنولوجيا التحلل الحراري بالبلازما، ما يتيح الاستفادة من الميثان والغاز الحيوي وغاز الاحتراق وغاز المدافن كمصادر صناعية. www.graforce.com

 Calderion وAudacia، يُعدّ Calderion، الذي تأسس على يد Audacia، صندوقًا صناعيًا متخصصًا في التكنولوجيا العميقة الصناعية ومكرسًا لتوسيع نطاق تقنيات وقود الجيل القادم. شركة Audacia مدرجة في بورصة Euronext Growth Paris. calderion.com | audacia.fr

 شركة Terravent، الشركة الاستثمارية المتخصصة في تطوير مشروعات تركز على الطاقات المتجددة والبنية التحتية المتكاملة للهيدروجين. وقد نجحت في تنفيذ مشروعات بطاقة إجمالية قيمتها واحد جيجاواط على مدار 25 عامًا. www.terravent.de

 Wen.Co.Invest، مكتب عائلي مقره مدينة أولدنبورغ، يستثمر في المشروعات الابتكارية الموجهة نحو تحقيق مبادئ الاستدامة لتحقيق تأثير إيجابي بعيد المدى. www.wegasupport.de

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

الرابط الثابت

https://www.aetoswire.com/ar/news/2602202653547

جهات الاتصال

المسؤول الإعلامي: الدكتور Jens Hanke، المدير التنفيذي لشركة Graforce GmbH، الهاتف: ‎+49 30 632222 110، presse@graforce.com

Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally

BERLIN - Wednesday, 25. February 2026

(BUSINESS WIRE)--The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH.

The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures.

Disruptive alternative to conventional processes

Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them.

The result is a high-efficiency production of clean hydrogen and syngas, while carbon is obtained as a high-purity industrial raw material that remains in material cycles. When biogenic feedstocks are used, the process enables a negative CO₂ footprint (Carbon Removal), as the carbon is permanently stored rather than released into the atmosphere. This modular approach allows for decentralized production directly at the point of consumption, significantly reducing transport costs and energy losses.

Strategic cooperation with RAG Austria AG

In parallel with the financing round, Graforce is deepening its partnership with energy storage company RAG Austria AG, which is providing targeted financial and industrial support for the further development of the methane plasma pyrolysis plant. The focus of the collaboration is on system optimization and industrial integration. This collaboration strengthens Graforce on its path to continuous industrial operation, increases plant efficiency, and supports the use of modular plants at locations with variable availability of renewable energies.

Use of Funds: Scale-up and market deployment

The funds will be used for technological advancement, the roll‑out of additional industrial plants, and international market development. Graforce plans to expand its production capacities to meet the rising demand from the steel, chemical, and transportation sectors.

Partner Statements

“With Graforce’s addition to our portfolio, Calderion strengthens its coverage of next-generation fuel value chains, combining CO₂ capture, plasma-based methane conversion and synthetic fuels. This enables integrated pathways from methane and CO₂ to low-carbon hydrogen and syngas, serving both industrial decarbonization and sustainable fuels for maritime and aviation. Graforce’s technology also offers natural hydrogen explorers a solution to valorize associated methane without CO₂ emissions,” explains Vincent Brillault, Founding Partner of Calderion.

“The flexibility to provide various product gases in a decentralized and emission-free manner closes a critical gap in the industrial value chain. We are contributing our project planning expertise to bring this technology to the global market,” adds Jens Rötteken, CEO of Terravent.

“This investment underscores the enormous potential of our plasmalysis technology for a sustainable energy transition. We look forward to working together to make our plasmalysis technology scalable and cost-effective,” says Dr. Jens Hanke, CEO of Graforce GmbH.

About the partners

Graforce GmbH – Pioneer of CO₂-free hydrogen and syngas technologies based on plasma pyrolysis, enabling the utilization of methane, biogas, flare and landfill gases as industrial resources. www.graforce.com

Calderion & Audacia – Initiated by Audacia, Calderion is an industrial deep-tech fund dedicated to scaling next-generation fuel technologies. Audacia is listed on Euronext Growth Paris. calderion.com | audacia.fr

Terravent – Investor and project developer with a focus on renewable energies and integrated hydrogen infrastructure. Over one gigawatt of projects realized in 25 years. www.terravent.de

Wen.Co.Invest – Oldenburg-based family office investing in innovative, sustainability‑oriented ventures for long‑term positive impact. www.wegasupport.de

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224703188/en/

Permalink

https://www.aetoswire.com/en/news/2502202653528

Contacts

Media Contact: Dr. Jens Hanke, CEO, Graforce GmbH, Phone: +49 30 632222 110, presse@graforce.com